EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

Kazuki Maesaka iD, Hayato Hikita iD, Machiko Kai, Yuki Tahata iD, Kumiko Shirai, Akira Doi, Kazuhiro Murai, Yoshinobu Saito, Ryoko Yamada, Takahiro Kodama iD, Kazuyoshi Ohkawa, Masanori Miyazaki und 18 weitere

Journal of Gastroenterology and Hepatology · 2025-10 · 40 (10) · 2580-2590

DOI: 10.1111/jgh.70068 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 09.09.2025. Verfasst von Kazuki Maesaka und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Bevacizumab, Carcinoma, Hepatocellular, Liver Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Atezolizumab plus bevacizumab is used as a first‐line treatment for unresectable hepatocellular carcinoma (uHCC). However, the relationship between its adverse events (AEs) and treatment efficacy remains unclear. In this study, we aimed to clarify this association.

Methods

This study included 187 patients with uHCC treated with atezolizumab plus bevacizumab as first‐line therapy at 19 affiliated hospitals in the Osaka Liver Forum. A landmark analysis was conducted to address biases in AE incidence.

Results

The objective response and disease control rates were 28.2% and 69.6%, respectively. The median progression‐free survival (PFS) and overall survival (OS) were 7.4 and 24.6 months, respectively. Among the 187 patients, 178 (95.2%) experienced at least one AE, with proteinuria being the most common (41.7%), followed by hypertension (34.8%) and fatigue (30.5%). All three major AEs had a median onset time of 6 weeks. We set the landmark point at Week 9 after treatment initiation, considering that the onset time for most AEs was within 9 weeks. In the landmark analysis, multivariable analysis identified the absence of bevacizumab interruption within 9 weeks and the occurrence of hypertension within 9 weeks as predictors of prolonged PFS. mALBI Grade 1/2a, the occurrence of hypertension, and the absence of fatigue and rash within 9 weeks were associated with prolonged OS. These results were consistent with those from the 6‐week landmark analysis.

Conclusions

Patients with hypertension occurring as an AE within 9 weeks are expected to have better PFS and OS with atezolizumab plus bevacizumab therapy for uHCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabCarcinoma, HepatocellularLiver NeoplasmsAntibodies, Monoclonal, HumanizedHypertensionAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedMiddle AgedTreatment OutcomeAged, 80 and overAdultProgression-Free SurvivalRetrospective Studies

Stichwörter der Autor:innen

adverse eventirAElandmark analysis

Substanzen

atezolizumabBevacizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Osaka, Japan.
  • Department of Gastroenterology and Hepatology, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.
  • Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Osaka, Japan.
  • Department of Gastroenterology and Hepatology, Osaka International Medical & Science Center, Osaka Keisatsu Hospital, Osaka, Osaka, Japan.
  • Department of Gastroenterology and Hepatology, Ikeda Municipal Hospital, Ikeda, Osaka, Japan.
  • Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan.

ORCID-Profile: Kazuki Maesaka, Hayato Hikita, Yuki Tahata, Takahiro Kodama, Ryotaro Sakamori, Tetsuo Takehara

Zitieren

APA

Maesaka, K., Hikita, H., Kai, M., Tahata, Y., Shirai, K., Doi, A., Murai, K., Saito, Y., Yamada, R., Kodama, T., Ohkawa, K., Miyazaki, M., Ishida, H., Matsumoto, K., Nozaki, Y., Yakushijin, T., Sakamori, R., Tatsumi, N., Iio, S., …, & Takehara, T. (2025). Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology, 40(10), 2580-2590. https://doi.org/10.1111/jgh.70068

Vancouver

Maesaka K, Hikita H, Kai M, Tahata Y, Shirai K, Doi A, et al. Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology. 2025;40(10):2580-2590. doi:10.1111/jgh.70068

BibTeX
@article{Maesaka2025,
  author = {Maesaka, Kazuki and Hikita, Hayato and Kai, Machiko and Tahata, Yuki and Shirai, Kumiko and Doi, Akira and Murai, Kazuhiro and Saito, Yoshinobu and Yamada, Ryoko and Kodama, Takahiro and Ohkawa, Kazuyoshi and Miyazaki, Masanori and Ishida, Hisashi and Matsumoto, Kengo and Nozaki, Yasutoshi and Yakushijin, Takayuki and Sakamori, Ryotaro and Tatsumi, Nobuyuki and Iio, Sadaharu and Nawa, Takatoshi and Kakita, Naruyasu and Nakahara, Masanori and Hosui, Atsushi and Usui, Takeo and Imanaka, Kazuho and Doi, Yoshinori and Sakakibara, Mitsuru and Yoshida, Yuichi and Tatsumi, Tomohide and Takehara, Tetsuo},
  title = {Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  volume = {40},
  number = {10},
  pages = {2580--2590},
  doi = {10.1111/jgh.70068}
}
Kostenlos starten →